Abstract
Pleiotrophin (PTN) is an 18 kDa growth factor that has high affinity for heparin and together with midkine form a family of structurally related heparin binding growth factors. Screening of various human tumour cell lines and tumour specimens of different origin revealed that PTN is expressed in many types of cancer, such as gliomas, melanomas, meningiomas, neuroblastomas, choriocarcinomas, leukemias and cancers of pancreas, prostate, stomach, colon, breast, ovaries and lungs. Concerning the biological activity of PTN in cancer, there is ample evidence that it is a tumour-promoting factor, while it has also been suggested that it may be implicated in cellular quiescence rather than an oncogenic phenotype. Besides a direct effect of PTN on tumour cells, there is also a plethora of reports indicating a positive correlation between PTN and in vivo or in vitro angiogenesis, a key step in the progress of many tumours. The identification of PTN domains responsible for its angiogenic and transforming activities is considered important, and data existing so far suggest distinct or even opposite effects for different PTN regions. This review summarises papers and patents dealing with the present understanding of PTN biochemistry, actions, mechanism(s) of action and implication in several diseases, with a special emphasis on its role in diverse tumour types.
Keywords: angiogenesis, cancer, growth factors, heparin affin regulatory peptide, pleiotrophin
Recent Patents on Anti-Cancer Drug Discovery
Title: Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Volume: 2 Issue: 2
Author(s): Constantinos Mikelis, Marina Koutsioumpa and Evangelia Papadimitriou
Affiliation:
Keywords: angiogenesis, cancer, growth factors, heparin affin regulatory peptide, pleiotrophin
Abstract: Pleiotrophin (PTN) is an 18 kDa growth factor that has high affinity for heparin and together with midkine form a family of structurally related heparin binding growth factors. Screening of various human tumour cell lines and tumour specimens of different origin revealed that PTN is expressed in many types of cancer, such as gliomas, melanomas, meningiomas, neuroblastomas, choriocarcinomas, leukemias and cancers of pancreas, prostate, stomach, colon, breast, ovaries and lungs. Concerning the biological activity of PTN in cancer, there is ample evidence that it is a tumour-promoting factor, while it has also been suggested that it may be implicated in cellular quiescence rather than an oncogenic phenotype. Besides a direct effect of PTN on tumour cells, there is also a plethora of reports indicating a positive correlation between PTN and in vivo or in vitro angiogenesis, a key step in the progress of many tumours. The identification of PTN domains responsible for its angiogenic and transforming activities is considered important, and data existing so far suggest distinct or even opposite effects for different PTN regions. This review summarises papers and patents dealing with the present understanding of PTN biochemistry, actions, mechanism(s) of action and implication in several diseases, with a special emphasis on its role in diverse tumour types.
Export Options
About this article
Cite this article as:
Constantinos Mikelis , Marina Koutsioumpa and Evangelia Papadimitriou , Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer, Recent Patents on Anti-Cancer Drug Discovery 2007; 2 (2) . https://dx.doi.org/10.2174/157489207780832405
DOI https://dx.doi.org/10.2174/157489207780832405 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Biology of Nucleoside Transporters and their Distributions and Functions in the Brain
Current Topics in Medicinal Chemistry Negative Glucocorticoid Receptor Response Elements and their Role in Glucocorticoid Action
Current Pharmaceutical Design ABC Transporters: Regulation and Association with Multidrug Resistance in Hepatocellular Carcinoma and Colorectal Carcinoma
Current Medicinal Chemistry Modulation of ABC Transporters by Nuclear Receptors: Physiological, Pathological and Pharmacological Aspects
Current Medicinal Chemistry Standardization of Epitopes for Human Chorionic Gonadotropin (hCG) Immunoassays
Current Medicinal Chemistry Cadmium as an Endocrine Disruptor in the Reproductive System
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Recent Developments of Steroid Sulfatase Inhibitors as Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?
Current Pharmaceutical Design Drug Targeting Approaches and Use of Drug Delivery Systems in Management of Cancer
Current Pharmaceutical Design Phosphorylation Processes Controlling Aromatase Activity in Br east Cancer: An Update
Mini-Reviews in Medicinal Chemistry Decoding the Knots of Initiation of Oncogenic Epithelial-Mesenchymal Transition in Tumor Progression
Current Cancer Drug Targets Dihydrofolate Reductase Gene Variations in Susceptibility to Disease and Treatment Outcomes
Current Genomics Gestational Trophoblastic Neoplasia, an Ancient Disease: New Light and Potential Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry Development of A Novel System Based on Green Magnetic / Graphene Oxide / Chitosan /Allium Sativum / Quercus / Nanocomposite for Targeted Release of Doxorubicin Anti-Cancer Drug
Anti-Cancer Agents in Medicinal Chemistry Ribosome-inactivating Proteins from Root Tubers and Seeds of Trichosan-thes kirilowii and Other Trichosanthes Species
Protein & Peptide Letters miRNAs Highlights in Stem and Cancer Cells
Mini-Reviews in Medicinal Chemistry Molecular Mechanisms Underlying Psychological Stress and Cancer
Current Pharmaceutical Design Prostaglandin J2 Family and the Cardiovascular System
Current Vascular Pharmacology Antiproliferative Efficacy of Angiotensin II Receptor Blockers in Prostate Cancer
Current Cancer Drug Targets 7-O-aminoalkyl-2,3-dehydrosilibinins: Synthesis and in vitro Anti-cancer Efficacy
Anti-Cancer Agents in Medicinal Chemistry